Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 5/20 | 0.55 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.55 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.55 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.55 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.55 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.55 |
| ▸ | HTR2B | P41595 | 1/20 | 0.55 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16953290 | 0.88 | GABRA1 (0.44) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL29661785 | 0.87 | GABRA1 (0.48) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL6679470 | 0.87 | GABRA1 (0.48) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL29515496 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL61794 | 0.85 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL9080666 | 0.84 | GABRA1 (0.46) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL11120667 | 0.83 | GABRA1 (0.44) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL22791943 | 0.83 | CYP1A2 (0.47) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL3604233 | 0.83 | GABRA1 (0.60) | GABRA1GABRB2GABRG2GABRB3GABRB1 | |
| SCHEMBL31634517 | 0.83 | GABRA1 (0.60) | GABRA1GABRB2GABRG2GABRB3GABRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028482-A1 | Substitution at the Central Position of Heptamethine Dyes By Aryllithium Addition for Improved Fluorophores | UNIV ARKANSAS (US) | 2026-01-29 | — | — | US | claimed |
| CN-119219455-A | Aromatic ring hydrogen-deuterium exchange reaction catalytic system and preparation method of deuterated aromatic hydrocarbon | 国科大杭州高等研究院 | 2024-12-31 | — | — | CN | claimed |
| CN-113788859-B | Large-steric-hindrance N-heterocyclic carbene-palladium complex, preparation method and application thereof, and synthetic method of sonchibu based on complex | 中山大学 | 2023-03-31 | — | — | CN | claimed |
| CN-113788859-A | Large-steric-hindrance N-heterocyclic carbene-palladium complex, preparation method and application thereof, and synthetic method of sonchibu based on complex | 中山大学 | 2021-12-14 | — | — | CN | claimed |
| CN-112209972-A | Large-steric-hindrance N-heterocyclic carbene-palladium complex, preparation method and application thereof, and synthetic method of sonchibu based on complex | 中山大学 | 2021-01-12 | — | — | CN | claimed |
| CN-106892945-A | A kind of N-heterocyclic carbine-palladium complex, its preparation method and application | 温州大学 | 2017-06-27 | — | — | CN | claimed |
| US-20260028482-A1 | Substitution at the Central Position of Heptamethine Dyes By Aryllithium Addition for Improved Fluorophores | UNIV ARKANSAS (US) | 2026-01-29 | — | — | US | disclosed |
| WO-2025261907-A1 | NONLINEAR OPTICAL DYES WITH IMPROVED STABILITY | SILORIX GMBH (DE) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667535-A1 | NONLINEAR OPTICAL DYES WITH IMPROVED STABILITY | SilOriX GmbH (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12473383-B2 | Transition metal catalysts for olefin polymerization | DOW GLOBAL TECHNOLOGIES LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250313662-A1 | IRON-CATALYZED METATHESIS POLYMERIZATION OF OLEFINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2025-10-09 | — | — | US | disclosed |
| EP-0797575-B1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | disclosed |
| US-6017905-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5959113-A | REACTING A DIKETONE DERIVATIVE WITH AN ALDEHYDE DERIVATIVE; ADMINISTERING TO TREAT ATHEROSCLEROSIS, PSORIASIS, ALOPECIA AND TUMORS | HOFFMANN-LA ROCHE INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5807846-A | TREATING HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| EP-0797575-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-01 | — | — | EP | disclosed |
| WO-1996018626-A1 | IMIDAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS IN PARTICULAR EGF-R TYROSINE KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-20 | — | — | WO | disclosed |
| US-3962307-A | HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GABRA1 4420/4885GABRB2 4475/4885GABRG2 2943/4885 |
| US-20250313662-A1 | IRON-CATALYZED METATHESIS POLYMERIZATION OF OLEFINS | PPOX, HMOX1, HMOX2 | GABRA1 4480/4885GABRB2 4349/4885GABRG2 4641/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | GABRA1 4420/4885GABRB2 4475/4885GABRG2 2943/4885 |
| US-12473383-B2 | Transition metal catalysts for olefin polymerization | SOD1, PPOX, HMOX1 | GABRA1 4308/4885GABRB2 3902/4885GABRG2 3783/4885 |
| US-20260028482-A1 | Substitution at the Central Position of Heptamethine Dyes By Aryllithium Addition for Improved Fluorophores | KCNK5, KCNA7, KCNA4 | GABRA1 1607/4885GABRB2 1007/4885GABRG2 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.